Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 8/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Snc-80 SCHEMBL7233538 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| Snc-80 SCHEMBL3366042 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| Snc-80 SCHEMBL12019443 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| Snc-80 SCHEMBL1514203 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| Snc-80 SCHEMBL1514202 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| Snc-80 SCHEMBL29489341 | 1.00 | OPRD1 (1.00) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| SCHEMBL4586923 | 0.94 | OPRD1 (0.89) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| SCHEMBL6935931 | 0.92 | CYP3A4 (0.85) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| SCHEMBL6935922 | 0.92 | CYP3A4 (0.85) | OPRD1OPRM1MEN1KMT2ACYP3A4 | |
| SCHEMBL5141891 | 0.90 | OPRD1 (0.82) | OPRD1OPRM1MEN1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158016-A1 | DELTA OPIOID RECEPTOR ANTAGONISTS REPROGRAM IMMUNOSUPPRESSIVE MICROENVIRONMENT TO BOOST IMMUNOTHERAPY | NATIONAL INSTITUTES OF HEALTH | 2023-05-25 | — | — | US | claimed |
| US-20230054895-A1 | METHODS FOR INDUCING BIOSTASIS IN A CELL, TISSUE OR ORGAN | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-02-23 | — | — | US | claimed |
| EP-4087395-A1 | METHODS FOR INDUCING BIOSTASIS IN A CELL, TISSUE OR ORGAN | President And Fellows Of Harvard College (US) | 2022-11-16 | — | — | EP | claimed |
| US-20200289489-A1 | COMBINATION FOR TREATING PAIN | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2020-09-17 | — | — | US | claimed |
| EP-3432884-A1 | COMBINATION FOR TREATING PAIN | Regents of the University of Minnesota (US) | 2019-01-30 | — | — | EP | claimed |
| WO-2017165558-A1 | COMBINATION FOR TREATING PAIN | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-09-28 | — | — | WO | claimed |
| WO-2006130471-A1 | THE USE DELTA OPIOID RECEPTOR AGONISTS AND/OR INVERSE AGONISTS TO INHIBIT THE CONSUMPTION OF SUBSTANCES OF ABUSE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-12-07 | — | — | WO | claimed |
| WO-2005079767-A2 | MEANS FOR MODULATION OF THE EFFECTS OF OPIOID-LIKE SUBSTANCES | Universitätsklinikum Münster (DE) | 2005-09-01 | — | — | WO | claimed |
| US-20260137691-A1 | WB3 FOR ANESTHESIA AND TREATING PAIN | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-05-21 | — | — | US | disclosed |
| US-20260115185-A1 | QUINOLINE DERIVATIVES WHICH ACT AS KAPPA-OPIOID RECEPTOR ANTAGONISTS | SCRIPPS RESEARCH INST (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4704874-A2 | MOLECULES AND METHODS OF USE THEREOF | Woolwich Sciences LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | UNIV WAKE FOREST HEALTH SCIENCES (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4687887-A2 | SPECIFIC REVERSAL AGENTS TO TREAT ACUTE AND CHRONIC TOXICITY OF FENTANYLS | Virginia Commonwealth University (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260022097-A1 | SELECTIVE OPIOID RECEPTOR AGONISTS AND ANTAGONISTS | THE US SECRETARY DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2026-01-22 | — | — | US | disclosed |
| US-6291675-B1 | MIXING OPIOID COMPOUND AND HYDRIDE REAGENT SELECTED FROM THE GROUP CONSISTING OF LITHIUM TRI-SEC-BUTYLBOROHYDRIDE, LITHIUM TRISIAMYLBOROHYDRIDE AND LITHIUM TRIETHYLBOROHYDRIDE TO PRODUCE AN O-DEMETHYLATED OPIOID COMPOUND | THE UNITED STATES AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2001-09-18 | — | — | US | disclosed |
| EP-1112255-A1 | 4,4-BIARYLPIPERIDINE DERIVATIVES WITH OPIOID RECEPTOR ACTIVITY | Pfizer Products Inc. (US) | 2001-07-04 | — | — | EP | disclosed |
| EP-1038872-A1 | 4-Phenyl-4-heteroarylpiperdine derivatives as opioid receptor ligands | Pfizer Products Inc. (US) | 2000-09-27 | — | — | EP | disclosed |
| US-6103722-A | CARDIOPROTECTIVE EFFECT; STIMULATION OF DELTA OPIOID RECEPTOR AGONISTS; ANTIISCHEMIC AGENTS; REDUCING MYOCARDIAL INFARCTION DAMAGE; 4A-(3-HYDROXYPHENYL)-1,2,3,4, 4A,5,12,12A-NAPHTHO(OR QUINOXALINO)(2,3-G)ISOQUINOLINES | THE MEDICAL COLLEGE OF WISCONSIN RESEARCH FOUNDATION INC. (US) | 2000-08-15 | — | — | US | disclosed |
| WO-2000039091-A1 | 3,3-BIARYLPIPERIDINE AND 2,2-BIARYLMORPHOLINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000014066-A1 | 4,4-BIARYLPIPERIDINE DERIVATIVES WITH OPIOID RECEPTOR ACTIVITY | PFIZER PRODUCTS INC. (US) | 2000-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158016-A1 | DELTA OPIOID RECEPTOR ANTAGONISTS REPROGRAM IMMUNOSUPPRESSIVE MICROENVIRONMENT TO BOOST IMMUNOTHERAPY | OPRD1, OPRM1, OPRK1 | OPRD1 1/4885OPRM1 2/4885MEN1 4757/4885 |
| US-20260137691-A1 | WB3 FOR ANESTHESIA AND TREATING PAIN | WNT3, TRPV3, ADRB3 | OPRD1 17/4885OPRM1 7/4885MEN1 4805/4885 |
| US-20260022097-A1 | SELECTIVE OPIOID RECEPTOR AGONISTS AND ANTAGONISTS | OPRM1, OPRD1, OPRK1 | OPRD1 2/4885OPRM1 1/4885MEN1 4873/4885 |
| US-20260115185-A1 | QUINOLINE DERIVATIVES WHICH ACT AS KAPPA-OPIOID RECEPTOR ANTAGONISTS | OPRK1, OPRD1, OPRM1 | OPRD1 2/4885OPRM1 3/4885MEN1 4878/4885 |
| US-20260060822-A1 | BIOENGINEERED SCAFFOLDS FOR VASCULAR GRAFTS AND METHODS OF USE THEREOF | PFKP, PBK, MYLK | OPRD1 4518/4885OPRM1 4810/4885MEN1 4716/4885 |
| US-20200289489-A1 | COMBINATION FOR TREATING PAIN | OPRL1, ACHE, OPRK1 | OPRD1 6/4885OPRM1 12/4885MEN1 4611/4885 |
| US-20230054895-A1 | METHODS FOR INDUCING BIOSTASIS IN A CELL, TISSUE OR ORGAN | OPRL1, OPRK1, OPRD1 | OPRD1 3/4885OPRM1 6/4885MEN1 4386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.